查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401165

全球抗菌藥物抗藥性監測市場：市場規模、佔有率、趨勢分析、機會、預測（2019-2029）

Antimicrobial Resistance Surveillance Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Solution ; By Application ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計2029年全球抗菌藥物抗藥性監測市場規模將達79.2億美元，2023年至2029年複合年成長率為5.6%，穩定成長。

由於擴大採用創新診斷技術來診斷和治療日益增加的醫院感染，全球抗菌藥物抗藥性監測市場正在蓬勃發展。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2022 年全球抗菌藥物抗藥性監測市場規模將達到 57.1 億美元。 BlueWeave 預測，在 2023-2029 年預測期內，全球抗菌素抗藥性監測市場規模將以 5.6% 的複合年成長率成長，到 2029 年將達到 79.2 億美元。全球抗菌素抗藥性監測市場的主要成長動力是：由抗藥性病原體引起的感染疾病發病率不斷增加、診斷技術的進步、對抗菌素抗藥性的日益關注以及解決抗菌素抗藥性的需求不斷增加。政府的配合措施和出現與藥物濫用相關的多重抗藥性。值得注意的是，先進的成像技術現在可以快速提供臨床資訊，而傳統的基於培養的方法可能需要長達 48 小時才能產生敏感性資料。無需冗長培養步驟即可檢測抗藥性的新技術的出現將診斷時間縮短了至少一天。更快、更先進的診斷測試預計將推動抗菌素抗藥性診斷市場的成長。此外，住院期間發生的院內感染包括多種疾病。醫院感染，如中心靜脈管相關的血流感染疾病和導管相關的泌尿道尿道感染感染疾病普遍。這些感染疾病的流行勢必會推動抗菌素抗藥性診斷市場的發展，反映出現代醫療保健中侵入性技術和設備的使用越來越多。然而，最終用戶與抗菌素抗藥性監測系統和套件相關的高成本和技術挑戰預計將限制預測期內的整體市場成長。

機會 -配合措施提高對抗菌素抗藥性及其控制的認知

抗菌素抗藥性 (AMR) 是對人類健康的一種廣泛的全球威脅，促使人們在 2015 年透過《抗菌素抗藥性全球行動計畫》(GAP-AMR) 採取統一應對措施。該舉措旨在透過負責任地提供有效、安全和有品質保證的藥物來確保感染疾病治療的持續成功。主導全球抗生素抗藥性和使用監測系統 (GLASS) 領導的監測對於政策制定和感染控制至關重要。 GLASS 標準化了資料收集、分析和解釋，促進涵蓋流行病學、臨床和人口層面資料的全面監測過渡。 GLASS 積極配合措施能力建設，並與世衛組織和區域網路合作，以填補知識空白、為策略資訊資訊並為全球抗微生物藥物抗藥性認知工作做出重大貢獻。

COVID-19 對全球抗菌藥物抗藥性監測市場的影響

COVID-19 大流行對全球抗菌藥物抗藥性監測市場產生了積極影響。有幾個因素導致了這種情況的惡化，包括對COVID-19 患者使用抗生素的增加、不堪重負的醫療系統內感染控制措施的中斷以及將資源從監測和應對抗菌素抗藥性(AMR) 的威脅轉移到其他地方。大流行需要引入虛擬諮詢和快速診斷測試，以最大程度地減少醫院就診次數。在疫情大流行後，家庭醫療保健仍然至關重要，特別是對於患有既往疾病的患者來說，並且預計將刺激對診斷測試的需求。

全球抗菌藥物抗藥性監測市場—按最終用戶

按最終用戶分類，全球抗菌素抗藥性監測市場分為醫院和診所部分以及研究和學術機構部分。醫院和診所部門在最終用戶的抗菌藥物抗藥性監測全球市場中佔有很高的佔有率，這主要是由於醫院和診所觀察到的患者密度不斷增加。由於醫院感染發生率不斷增加，維持嚴格的感染控制方案是必要的基本的。

全球抗菌素抗藥性監測市場—按地區

本研究報告調查分析了全球抗菌藥物抗藥性監測市場，並列出了五個主要地區的各國市場。這些地區是北美、歐洲、亞太地區、拉丁美洲和中東/非洲。北美在全球抗菌藥物抗藥性監測市場中佔最高佔有率。該地區的優勢在於其在美國和加拿大擁有完善的醫療保健系統和先進的檢測設施。這些主要國家正在大力投資抗菌素抗藥性 (AMR) 監測，重點是臨床診斷和資料收集。該地區強大的醫療基礎設施和高標準的患者照護支持北美臨床診斷的很大佔有率。值得注意的是，美國疾病管制與預防中心 (CDC) 正在帶頭進行抗菌素抗藥性監測工作。同時，亞太地區預計在預測期內將呈現最快的成長率。特別是中國，在抗菌素抗藥性監測方面進行了大量投資，並建立了全國性的資料收集網路。與世界衛生組織（WHO）等國際組織的合作進一步加強了該地區的配合措施。亞太地區擁有不同的醫療保健系統和人口規模，包括中國和印度，並面臨著獨特的挑戰，導致區域和全球衛生組織推動的公共衛生監測工作配合措施。

競爭形勢

全球抗菌藥物抗藥性監測市場的主要企業包括 Becton Dickinson、bioMérieux、Thermo Fisher Scientific、Danaher、Luminex、Bruker、Bio-Rad、Qiagen 和 Abbott Laboratories、Roche Diagnostics、Opgen、Wolters Kluwer、Lumed、Biospace 和造父變星。為了進一步增加市場佔有率，這些公司正在採取各種策略，例如併購、合作、合資、授權協議和新產品發布。

該報告的詳細分析提供了有關全球抗菌素抗藥性監測市場的成長潛力、未來趨勢和統計數據的資訊。它還涵蓋了推動市場總規模預測的因素。該報告致力於提供全球抗菌素抗藥性監測市場的最新技術趨勢以及產業見解，以幫助決策者做出明智的策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第 2 章執行摘要

第 3 章：全球抗菌藥物抗藥性監測市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 診斷技術不斷創新
      • 醫院感染增加
    • 抑制因素
      • 與抗菌藥物抗藥性監測系統和套件相關的高成本
      • 最終用戶技術挑戰
    • 機會
      • 意識提升的配合措施
      • 新興經濟體的成長機會
    • 任務
      • 複雜的法律規範
  • 科技進步/最新發展
  • 法律規範
  • 波特五力分析

第4章全球抗菌藥物抗藥性監測市場概述

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按解決方案
      • 診斷套件
      • 診斷系統
      • 監控軟體
      • 服務
    • 按用途
      • 臨床診斷
      • 公共衛生監測
      • 其他
    • 按最終用戶
      • 醫院/診所
      • 研究/學術機構
      • 其他
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第5章北美抗菌藥物抗藥性監測市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按解決方案
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 加拿大

第6章歐洲抗菌藥物抗藥性監測市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按解決方案
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 歐洲其他地區

第7章亞太地區抗菌藥物抗藥性監測市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按解決方案
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲/紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他亞太地區

第8章拉丁美洲抗菌藥物抗藥性監測市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按解決方案
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第9章中東和非洲抗菌藥物抗藥性監測市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按解決方案
    • 按用途
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東/非洲

第10章競爭形勢

  • 主要企業及產品列表
  • 2022 年全球抗菌藥物抗藥性監測市場佔有率分析
  • 透過管理參數進行競爭基準化分析
  • 主要策略發展（合併、收購、合作夥伴關係等）

第11章 COVID-19 對全球抗生素抗藥性監測市場的影響

第12章 公司簡介

  • Becton, Dickinson and Company
  • Biomerieux
  • Thermo Fisher Scientific
  • Danaher
  • Luminex Corporation
  • Bruker
  • Bio-Rad
  • Qiagen
  • Abbott Laboratories
  • Roche Diagnostics
  • OpGen, Inc.
  • Wolters Kluwer NV
  • Lumed
  • BioSpace
  • Cepheid
  • 其他主要企業

第13章 關鍵策略建議

第14章調查方法

簡介目錄
Product Code: BWC231035

Global Antimicrobial Resistance Surveillance Market Size Expands at Steady CAGR of 5.6% During 2023-2029 to Touch USD 7.92 Billion by 2029

Global Antimicrobial Resistance Surveillance Market is flourishing because of increasing adoption of innovative diagnostic technologies to diagnose and treat growing incidences of hospital-acquired infections.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Antimicrobial Resistance Surveillance Market size at USD 5.71 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects Global Antimicrobial Resistance Surveillance Market size to grow at a CAGR of 5.6% reaching a value of USD 7.92 billion by 2029. Major growth drivers for the Global Antimicrobial Resistance Surveillance Market include an increasing incidence of infections attributed to drug-resistant pathogens, advancements in diagnostic technologies, a rising concern over antimicrobial resistance, governmental efforts to address antimicrobial resistance, and the emergence of multi-drug resistance linked to drug abuse. Notably, advanced imaging technologies now deliver clinical information swiftly, contrasting with traditional culture-based methods taking up to 48 hours for susceptibility data. The emergence of new techniques detecting drug resistance without lengthy culture processes shortens the diagnostic timeframe by at least a day. Faster and more advanced diagnostic tests are expected to drive growth in the antimicrobial resistance diagnostics market. Also, nosocomial infections, acquired during hospitalization, encompass diverse illnesses. Hospital-acquired infections, such as central line-associated bloodstream infections and urinary tract infections from catheters, are widespread. The prevalence of these infections is poised to boost the antimicrobial resistance diagnostics market, reflecting the growing use of invasive techniques and equipment in modern healthcare. However, high costs associated with antimicrobial resistance surveillance system and kits and technical challenges in the end-user are anticipated to restrain the overall market growth during the forecast period.

Opportunity - Initiatives to Increase Awareness about Antimicrobial Resistance and Control

Antimicrobial resistance (AMR) is a pervasive global threat to human health, prompting a unified response through the Global Action Plan for AMR (GAP-AMR) in 2015. The initiative aims to ensure sustained success in treating infectious diseases by providing effective, safe, and quality-assured medicines responsibly. Surveillance, led by the Global Antimicrobial Resistance and Use Surveillance System (GLASS), is pivotal for policy formulation and infection control. GLASS standardizes data collection, analysis, and interpretation, promoting a shift towards comprehensive surveillance encompassing epidemiological, clinical, and population-level data. It actively engages in capacity building and partners with WHO and regional networks to bridge knowledge gaps and inform strategies, contributing significantly to global AMR awareness initiatives.

Impact of COVID-19 on Global Antimicrobial Resistance Surveillance Market

COVID-19 pandemic had a positive impact on Global Antimicrobial Resistance Surveillance Market. Several factors contributed to this exacerbation, including heightened antibiotic use for COVID-19 patients, disruptions in infection control measures within overwhelmed healthcare systems, and the redirection of resources away from monitoring and addressing antimicrobial resistance (AMR) threats. The pandemic necessitated the adoption of virtual visits and rapid diagnostic testing to minimize hospital visits. Even post-pandemic, home-based healthcare is expected to remain essential, particularly for individuals with pre-existing conditions, thereby fueling the demand for diagnostic assays.

Global Antimicrobial Resistance Surveillance Market - By End User

On the basis of end user, the Global Antimicrobial Resistance Surveillance Market is split into Hospitals & Clinics and Research & Academic Institutes segments. The hospitals & clinics segment holds a higher share in the Global Antimicrobial Resistance Surveillance Market by end user, primarily due to the elevated patient density observed in hospitals and clinics, the rising incidence of nosocomial infections within hospital settings, and the imperative to uphold stringent infection control protocols.

Global Antimicrobial Resistance Surveillance Market - By Region

The in-depth research report on the Global Antimicrobial Resistance Surveillance Market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America region holds the highest share in the Global Antimicrobial Resistance Surveillance Market. The region's dominance is attributed to its well-established healthcare systems and advanced laboratory facilities in the United States and Canada. These major countries exhibit substantial investments in antimicrobial resistance (AMR) surveillance, with a specific focus on clinical diagnostics and data collection. The region's robust healthcare infrastructure and high standards of patient care contribute to the significant share held by clinical diagnostics in North America. Notably, the Centers for Disease Control and Prevention (CDC) in the United States spearhead AMR surveillance efforts. Meanwhile, the Asia Pacific region is expected to witness the fastest growth rate during the forecast period. China, in particular, has made noteworthy investments in AMR surveillance, establishing a national data collection network. Collaboration with international organizations, such as the World Health Organization (WHO), further enhances the region's efforts. The Asia Pacific region, encompassing diverse healthcare systems and population sizes, including China and India, encounters distinct challenges, prompting an upsurge in public health surveillance initiatives facilitated by regional and global health organizations.

Competitive Landscape

Major players operating in the Global Antimicrobial Resistance Surveillance Market include Becton, Dickinson and Company, Biomerieux, Thermo Fisher Scientific, Danaher, Luminex Corporation, Bruker, Bio-Rad, Qiagen, Abbott Laboratories, Roche Diagnostics, OpGen, Inc., Wolters Kluwer N.V., Lumed, BioSpace, and Cepheid. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antimicrobial Resistance Surveillance Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antimicrobial Resistance Surveillance Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Antimicrobial Resistance Surveillance Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing innovation in diagnostic technologies
      • 3.2.1.2. Increasing incidences of hospital-acquired infections
    • 3.2.2. Restraints
      • 3.2.2.1. High costs associated with antimicrobial resistance surveillance system and kits
      • 3.2.2.2. Technical challenges in the End User
    • 3.2.3. Opportunities
      • 3.2.3.1. Awareness initiatives for antimicrobial resistance and control
      • 3.2.3.2. Growth opportunities in emerging economies
    • 3.2.4. Challenges
      • 3.2.4.1. Complex regulatory framework
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Antimicrobial Resistance Surveillance Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Solution
      • 4.2.1.1. Diagnostic kits
      • 4.2.1.2. Diagnostic systems
      • 4.2.1.3. Surveillance software
      • 4.2.1.4. Services
    • 4.2.2. By Application
      • 4.2.2.1. Clinical Diagnostics
      • 4.2.2.2. Public Health Surveillance
      • 4.2.2.3. Other
    • 4.2.3. By End User
      • 4.2.3.1. Hospitals & Clinics
      • 4.2.3.2. Research & Academic Institutes
      • 4.2.3.3. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Antimicrobial Resistance Surveillance Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Solution
    • 5.2.2. By Application
    • 5.2.3. By End User
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Solution
      • 5.2.4.1.2. By Application
      • 5.2.4.1.3. By End User
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Solution
      • 5.2.4.2.2. By Application
      • 5.2.4.2.3. By End User

6. Europe Antimicrobial Resistance Surveillance Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Solution
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Solution
      • 6.2.4.1.2. By Application
      • 6.2.4.1.3. By End User
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Solution
      • 6.2.4.2.2. By Application
      • 6.2.4.2.3. By End User
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Solution
      • 6.2.4.3.2. By Application
      • 6.2.4.3.3. By End User
      • 6.2.4.4. France
      • 6.2.4.4.1. By Solution
      • 6.2.4.4.2. By Application
      • 6.2.4.4.3. By End User
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Solution
      • 6.2.4.5.2. By Application
      • 6.2.4.5.3. By End User
      • 6.2.4.6. Belgium
      • 6.2.4.6.1. By Solution
      • 6.2.4.6.2. By Application
      • 6.2.4.6.3. By End User
      • 6.2.4.7. Russia
      • 6.2.4.7.1. By Solution
      • 6.2.4.7.2. By Application
      • 6.2.4.7.3. By End User
      • 6.2.4.8. The Netherlands
      • 6.2.4.8.1. By Solution
      • 6.2.4.8.2. By Application
      • 6.2.4.8.3. By End User
      • 6.2.4.9. Rest of Europe
      • 6.2.4.9.1. By Solution
      • 6.2.4.9.2. By Application
      • 6.2.4.9.3. By End User

7. Asia Pacific Antimicrobial Resistance Surveillance Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Solution
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Solution
      • 7.2.4.1.2. By Application
      • 7.2.4.1.3. By End User
      • 7.2.4.2. India
      • 7.2.4.2.1. By Solution
      • 7.2.4.2.2. By Application
      • 7.2.4.2.3. By End User
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Solution
      • 7.2.4.3.2. By Application
      • 7.2.4.3.3. By End User
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Solution
      • 7.2.4.4.2. By Application
      • 7.2.4.4.3. By End User
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Solution
      • 7.2.4.5.2. By Application
      • 7.2.4.5.3. By End User
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Solution
      • 7.2.4.6.2. By Application
      • 7.2.4.6.3. By End User
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Solution
      • 7.2.4.7.2. By Application
      • 7.2.4.7.3. By End User
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Solution
      • 7.2.4.8.2. By Application
      • 7.2.4.8.3. By End User
      • 7.2.4.9. Vietnam
      • 7.2.4.9.1. By Solution
      • 7.2.4.9.2. By Application
      • 7.2.4.9.3. By End User
      • 7.2.4.10. Rest of APAC
      • 7.2.4.10.1. By Solution
      • 7.2.4.10.2. By Application
      • 7.2.4.10.3. By End User

8. Latin America Antimicrobial Resistance Surveillance Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Solution
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Solution
      • 8.2.4.1.2. By Application
      • 8.2.4.1.3. By End User
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Solution
      • 8.2.4.2.2. By Application
      • 8.2.4.2.3. By End User
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Solution
      • 8.2.4.3.2. By Application
      • 8.2.4.3.3. By End User
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Solution
      • 8.2.4.4.2. By Application
      • 8.2.4.4.3. By End User
      • 8.2.4.5. Rest of LATAM
      • 8.2.4.5.1. By Solution
      • 8.2.4.5.2. By Application
      • 8.2.4.5.3. By End User

9. Middle East & Africa Antimicrobial Resistance Surveillance Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Solution
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Solution
      • 9.2.4.1.2. By Application
      • 9.2.4.1.3. By End User
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Solution
      • 9.2.4.2.2. By Application
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Solution
      • 9.2.4.3.2. By Application
      • 9.2.4.3.3. By End User
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Solution
      • 9.2.4.4.2. By Application
      • 9.2.4.4.3. By End User
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Solution
      • 9.2.4.5.2. By Application
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Solution
      • 9.2.4.6.2. By Application
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Solution
      • 9.2.4.7.2. By Application
      • 9.2.4.7.3. By End User
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Solution
      • 9.2.4.8.2. By Application
      • 9.2.4.8.3. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Antimicrobial Resistance Surveillance Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Antimicrobial Resistance Surveillance Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Becton, Dickinson and Company
  • 12.2. Biomerieux
  • 12.3. Thermo Fisher Scientific
  • 12.4. Danaher
  • 12.5. Luminex Corporation
  • 12.6. Bruker
  • 12.7. Bio-Rad
  • 12.8. Qiagen
  • 12.9. Abbott Laboratories
  • 12.10. Roche Diagnostics
  • 12.11. OpGen, Inc.
  • 12.12. Wolters Kluwer N.V.
  • 12.13. Lumed
  • 12.14. BioSpace
  • 12.15. Cepheid
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations